- About the Lecture
-
About the Lecture
Genzyme is a leader in personalized medicine, as Mark Bamforth demonstrates. For instance, the company collects cartilage from a single patient, grows it in the lab, and sends it back securely to that same patient. The system, says Bamforth, tolerates “no mix ups.” But the company also deals in drugs sent to hundreds of thousands of kidney dialysis patients. Each kind of product must adhere to a specific kind of manufacturing and distribution process, and the regulations of the FDA and other countries. Bamforth must navigate “a complexity and diversity of supply chains.”
Peter Walsh works behind the scenes at UPS, making sure those brown trucks deliver to the right location at the right time. He believes that “healthcare is a good 20 to 30 years behind other industries” in terms of getting the goods from supplier to manufacturer to consumer. “We see in big pharma a silo approach. That needs to change … and means sharing of information—scary to think of in this industry.”
Abbott Weiss sees in pharmaceuticals “a highly fragmented set of supply chains” at a time when globalization poses increased risks, such as theft and diversion, and cost pressures. He describes working at Polaroid, and shipping out 120 million packs of film a year, with 140 countries each requiring different labeling. “Exception management is the rule in supply chains,” says Weiss. And unlike film, there are “life and death implications of getting the right medicine at the right time and right place.” The good news is that much of the technology for solving tracking and distribution problems already exists, Weiss says.
One such technology, radio frequency identification (RFID), is a good first enabling step for pharmaceutical makers, says Daniel Engels. “If I know what I have and where it is, I can do something about it.” The critical problem will be “asset visibility,” communicating this unique product information to suppliers and customers. And this kind of tagging will prove especially difficult for generic or bulk drugs, sent through distributors. The “end game” is information sharing.
Related Videos
-
Innovation in Post-Launch Surveillance and Pharmaco-Vigilance
(Part Two)Névine Zariffa, John Glaser, Randall Lutter and Joanna Haas
August 18, 2005
-
Defining the Challenges Surrounding Innovation and Safety (Part One)
Una Ryan, Robert Spiegel, Robert Tepper, John Fallon and Ernst Berndt
August 18, 2005
-
What Can We Learn From Related Industries?
Andrew Parece, Tamsin Randlett and Stephen Sammut
August 12, 2004
-
- About the Speakers
-
About the Speakers
Moderator: Charles L. Cooney SM '67, PhD '70
Professor of Chemical and Biochemical Engieering Co-Director, Program on the Pharmaceutical Industry
Charles Cooney joined the faculty of MIT as an Assistant Professor in 1970, and as a full Professor in 1982. From 1995-2001 he was the executive officer of the Department of Chemical Engineering. He serves as a consultant to a number of biotech and pharmaceutical companies, is on the board of directors of Genzyme and CUNO, Inc. and is on several editorial boards of professional journals.
He obtained his M.S. and Ph.D. degree in Biochemical Engineering from MIT.Mark R. Bamforth
Senior Vice President, Corporate Operations and Pharmaceutical
Genzyme CorporationPeter Walsh
Director of Business Development, UPS Consulting
Abbot Weiss
Senior Lecturer
MIT Center for Transportation and LogisticsDaniel W. Engels
Director, R.F.I.D. Healthcare Initiative
- About the Host
-
About the Host
MIT Center for Biomedical Innovation
Video Player
Innovation in Manufacturing and Distribution Systems (Part Three)
- Moderator: Charles L. Cooney SM '67, PhD '70
- Mark R. Bamforth
Peter Walsh
Abbot Weiss
Daniel W. Engels - August 18, 2005
- Running Time: 1:27:19
Host
Series
Event Co-Sponsors
